MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
Adaptimmune Therapeutics plc Operating Cycle 2011-2026 | ADAP
Annual Operating Cycle Adaptimmune Therapeutics plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 55 | 26.4 | 6.41 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55 | 6.41 | 28.2 |
Quarterly Operating Cycle Adaptimmune Therapeutics plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 468 | 1.03 K | - | 16.6 | 3.82 | 74.1 | - | 23.4 | 41.7 | 8.77 | - | 11.6 | 15 | 32.9 | - | 144 | 31.8 | 14.6 | - | 10.6 | 12.6 | - | - | 733 | 1.11 K | - | - | 0.43 | 1.94 | 2.22 | - | 0.69 | 5.34 | 26.9 | - | 55.9 | 206 | 11.7 | - | 13.7 | 24.4 | 3.78 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 K | 0.43 | 138 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Altimmune
ALT
|
15.1 K | $ 4.2 | -2.67 % | $ 298 M |  USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.24 | -3.44 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.8 | 1.87 % | $ 4.36 M |  China |
 |
Aptevo Therapeutics
APVO
|
191 | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Aquestive Therapeutics
AQST
|
181 | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
43.2 | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
1.05 K | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 25.33 | -6.1 % | $ 3.22 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arvinas
ARVN
|
4.66 | $ 12.97 | -2.3 % | $ 920 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Atossa Therapeutics
ATOS
|
249 | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Atara Biotherapeutics
ATRA
|
50.4 | $ 5.01 | -7.47 % | $ 37.5 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
659 | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
116 | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
273 | $ 162.28 | -0.98 % | $ 8.07 B | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.56 | -0.58 % | $ 16.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |